Otsuka Pharmaceutical Development & Commercialization Inc. — Sponsor Intelligence | 12 EU Trials

Filter these 12 trials by condition, phase, country and more.

Open in Search →

12 Registered trials

5 Recruiting

8 Completed trials

21 Countries active

5 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase I (Other)

Phase III: 5 Phase II/III: 2 Phase II: 1 Phase I: 1 Phase I (Other): 3

Oversight events:

2 corrective measures across 2 trials

View oversight register →

100%

8 of 8 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Dementia Alzheimer's type 2 Tuberculosis 1 IgA nephropathy 1 Generalised anxiety disorder 1

Top IMPs

QUINIDINE SULFATE, DEUDEXTROMETHORPHAN HYDROBROMIDE 2 SIBEPRENLIMAB 2 TOLVAPTAN 2 REPINATRABIT 1 ULOTARONT 1

All trials

12 total

A phase 1 trial to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of VIS171 in participants with … Recruiting

2024-518976-30-00 Phase I (Other) 4 countries
A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 days to less than … Recruiting

2023-508218-41-00 Phase III 4 countries TOLVAPTAN
A Phase 3 Study of JNT-517 in Participants with Phenylketonuria Recruiting

2024-519554-37-00 Phase III 7 countries REPINATRABIT
A Trial to Examine the Effects of MSP-2020 on Brain Activity in Healthy Adults Recruiting

2025-522930-29-00 Phase I (Other) 1 country
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN). Recruiting

2023-507233-19-00 Phase II/III 12 countries SIBEPRENLIMAB
Trial of Sibeprenlimab in the Treatment of Sjögren’s Disease Ended

2024-516295-14-00 Phase II 6 countries SIBEPRENLIMAB
A Trial to Determine if Quabodepistat is Processed Differently in Adults with Reduced Liver Function Compared to Adults with Normal Liver Fu… Ended

2025-521502-18-00 Phase I (Other) 1 country
A Clinical Study that will measure how well SEP-363856 works and how safe it is in adults with Generalized Anxiety Disorder Ended

2022-502077-42-00 Phase II/III 6 countries ULOTARONT
A Phase I (First-in-Human) Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and… Ended

2023-504450-35-00 Phase I 1 country
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's … Ended

2023-504991-31-00 Phase III 8 countries QUINIDINE SULFATE, DEUDEXTROMETHORPHAN HYDROBROMIDE
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's … Ended

2023-504990-19-00 Phase III 7 countries QUINIDINE SULFATE, DEUDEXTROMETHORPHAN HYDROBROMIDE
A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 days to less than … Ended

2023-508217-17-00 Phase III 4 countries TOLVAPTAN

Showing 1–12 of 12 trials

← All sponsors A–Z